Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study for Patients with Cardiovascular and Metabolic Diseases

 Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study for Patients with Cardiovascular and Metabolic Diseases

Akcea and Ionis Report Results of AKCEA-ANGPTL3-LRx in P-II Study for Patients with Cardiovascular and Metabolic Diseases

Shots:

  • The P-II study involves assessing AKCEA-ANGPTL3-LRx (SC, 40-80mg) vs PBO in 105 patients with hypertriglyceridemia, T2D, and NAFLD for 6mos.
  • The P-II study resulted in meeting its primary & multiple secondary endpoints with a reduction in fasting triglycerides, ANGPTL3, apoC-III, VLDL-C, non-HDL cholesterol, no reduction in liver fat and is well tolerated
  • AKCEA-ANGPTL3-LRx is an investigational antisense therapy, designed to reduce the production of ANGPTL3. Additionally, in 2019, Akcea signed a WW exclusive license agreement with Pfizer for the therapy under which Pfizer is responsible for all development and regulatory activities and costs beyond those associated with P-II study

Click here ­to­ read full press release/ article | Ref: Akcea | Image: Akcea

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post